A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Chimeric-anti-CD37-Antibody-Radionuclide-Conjugate (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 06 Jun 2017 New trial record
- 24 May 2017 According to a Nordic Nanovector media release, the trial is expected to begin in 2H 2017.